Overview A Study to Evaluate the Efficacy and Safety of SHR0302 in Patients With Ankylosing Spondylitis Status: Recruiting Trial end date: 2023-02-23 Target enrollment: Participant gender: Summary This study is to evaluate the efficacy and safety of different doses of JAK1 inhibitor SHR0302 in subjects with active ankylosing spondylitis. Phase: Phase 2/Phase 3 Details Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.